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Abstract 
This study investigated the effects of acute branched-chain amino acid (BCAA) 
supplementation on recovery from exercise-induced muscle damage, among experienced 
resistance-trained athletes. In a double-blind matched-pairs design, 16 resistance-trained 
participants, routinely performing hypertrophy training, were randomly assigned to a BCAA 
(n = 8) or placebo (n = 8) group. The BCAAs were administered at a dosage of 0.087 g/kg body 
mass, with a 2:1:1 ratio of leucine, isoleucine and valine. The participants performed 6 sets of 
10 full-squats at 70 % 1RM to induce muscle damage. All participants were diet-controlled 
across the study. Creatine kinase (CK), peak isometric knee-extensor force, perceived muscle 
soreness and counter-movement jump (CMJ) height were measured immediately before 
(baseline), 1-h, 24-h and 48-h post-exercise. There were large to very large time effects for all 
measurements between baseline and 24-48 h. Between-group comparisons, expressed as a 
percentage of baseline, revealed differences in isometric strength at 24-h (Placebo ~87% c.f. 
BCAA ~92 %; moderate, likely), CMJ at 24-h (Placebo ~93 % c.f. BCAA ~96 %; small, likely) 
and muscle soreness at both 24-h (Placebo ~685 % c.f. BCAA ~531 %; small, likely) and 48-h 
(Placebo ~468 % c.f. BCAA ~350 %; small, likely). Acute supplementation of BCAAs (0.087 
g/kg) increased the rate of recovery in isometric strength, CMJ height and perceived muscle 
soreness compared to placebo after a hypertrophy-based training session among diet-
controlled, resistance-trained athletes. These findings question the need for longer BCAA 
loading phases and highlight the importance of dietary control in studies of this type. 
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Introduction  
  
Habitual resistance exercise can be used to increase muscle strength and compensatory growth 
known as ‘hypertrophy’ (Goldberg et al., 1975). Whilst the optimal training regime to increase 
muscle mass has not yet been established (Carpinelli et al., 2004; Philips, 2009; Mitchell et al., 
2012), it is typical for athletes to perform between 3-5 repeated bouts of resistance exercise to 
fatigue per micro-cycle (ACSM, 2009). These sessions commonly comprise 2-6 sets of 
resistance exercise, targeting major muscle groups, at intensities ranging from 6-12 maximum 
repetitions (RM) to failure (ACSM, 2009). Performing resistance exercise in this manner is 
partly intended to create mechanical tension, thus disturbing the integrity of skeletal muscle 
(Schoenfeld, 2010; 2012). It has been postulated that the exercise–induced muscle damage 
(EIMD) caused by resistance exercise initiates a cascade of intracellular signalling processes 
that upregulate the synthesis of muscle proteins and increase cell size (Schoenfeld, 2012). In 
the days (24-72 hours) after performing this type of exercise, participants are likely to 
experience symptoms of EIMD, such as delayed-onset muscle soreness (DOMS), decreased 
force production and leakage of intramuscular proteins into circulation (i.e. creatine kinase; 
CK) (Sorichter et al., 1999).  
 
Recovery from EIMD is an important part of the adaptive process, which can take up to 72 
hours (Barnett, 2006; Howatson and van Someren, 2008; Nedelec et al., 2013). Given the 
demands of frequent resistance training, full and rapid recovery between bouts of exercise is 
desirable. Interventions that help to attenuate the effects of muscle damage would, therefore, 
be beneficial to the athlete by reducing the decline in physical function, thus permitting greater 
engagement with training in the days following exercise (Cheung et al., 2003; Proske and 
Morgan, 2001; Howatson and van Someren, 2008). Furthermore, interventions that lower the 
perception of fatigue and DOMS or maintain the intracellular anabolic environment would also 
support the training or adaptation process. Branched-chain amino acids (BCAAs), in particular 
  
leucine, are commonly used as prophylactic interventions to attenuate symptoms of muscle 
damage (da Luz et al., 2011). Leucine supplementation has also been suggested to suppress 
muscle proteolysis (Zanchi et al., 2008) and reduce protein oxidation (Shimomura et al., 2009) 
after muscle-damaging exercise, thus maintaining the integrity of the sarcolemma. Indeed, the 
appearance of indirect markers of muscle damage, such as CK, have been reduced by both 
short- (Nosaka et al., 2006; Kirby et al., 2012; Shimomura et al., 2010) and long-term amino 
acid supplementation (loading) periods (Coombes and McNaughton, 2000; Howatson et al., 
2012; Sharp and Pearson, 2010). The attenuation in CK efflux after BCAA supplementation 
has been linked to a reduction in secondary damage, caused by the inflammatory response 
(Howatson and van Someren, 2008). The dampening of acute inflammatory responses might 
also explain the commonly-reported reductions in DOMS following mixed amino acid (Nosaka 
et al., 2006), isolated leucine (Kirby et al., 2012) or mixed BCAA supplementation 
(Shimomura et al., 2010; Howatson et al., 2012). Reductions in DOMS and cell damage might, 
in turn, explain the accelerated recovery of muscle function after leucine or mixed BCAA 
supplementation (Kirby et al., 2012; Howatson et al., 2012). 
 
There are numerous inconsistencies and limitations among previous studies that question the 
assumed recovery properties of BCAAs. Firstly, only one study has used participants with a 
recent resistance-training history (Howatson et al., 2012). Whilst it is suggested to omit 
resistance-trained participants from muscle-damage studies because of the repeated-bout effect 
(RBE) (McHugh, 2003), several studies have found that protective adaptation is absent 
amongst resistance-trained men and well-trained athletes (Bloomer et al., 2006; Falvo et al., 
2007; Falvo et al., 2009). Indeed, if the RBE is absent amongst this population, it increases the 
efficacy of BCAA supplementation among athletes who are training regularly and, most likely, 
require strategies to hasten recovery between training sessions. Furthermore, there has been no 
  
study to assess the efficacy of BCAA supplementation among resistance-trained athletes 
following a bout of hypertrophy-type exercise, opposed to eccentrically-biased exercise (i.e. 
100 drop-jumps; Howatson et al., 2012). This is important, given that a recent study has 
suggested that that the efficacy of BCAA supplementation as a recovery agent is dependent on 
the degree of muscle damage, and it is likely to be more effective after ‘moderate’ muscle 
damage (Fouré et al., 2016), such as that induced by performing non-ballistic 
concentric/eccentric lifting patterns, realistic of hypertrophy training programmes. 
Additionally, the evidence to support the optimal timing of BCAA supplementation for 
recovery from EIMD is equivocal, with research showing positive effects after 30 min of pre-
exercise supplementation (Howatson et al., 2012; Kirby et al., 2012), compared to others who 
have supplemented for up to three weeks (Sharp and Pearson, 2010). That 30 min of pre-
exercise BCAA is sufficient to reduce markers of EIMD is consistent with its 1-2 hour peak 
bioavailability following ingestion (Dickinson et al., 2014; Fouré et al., 2016). This also 
indicates that longer supplementation periods might be unnecessary to promote recovery from 
muscle damage, whilst also incurring a greater financial cost for athletes. Lastly, only one study 
has monitored the dietary intake (Jackman et al., 2010) of participants, meaning that the amount 
of protein and other macronutrients ingested is often unaccounted for. This is important since 
the energy content and protein included in a diet might optimise the recovery of subjects, 
independent of the BCAA supplement.  
 
Based on the above reasoning, the aim of this study was to investigate the effects of acute body-
mass dependent BCAA supplementation on recovery from specific EIMD, among athletes who 
take part in long-term training programmes, designed to induce muscle hypertrophy. It was 
hypothesized that the BCAA supplementation would attenuate the reductions in muscle 
  
function and increases in DOMS, as well as lowering the biochemical responses, compared to 
the placebo group.  
 
Methods 
Participants 
Fourteen males (mean ± SD age 21.8 ± 1.6 years, stature 183.3 ± 6.2 cm, body mass 95.1 ± 
11.8 kg, 1RM Squat 175 ± 32 kg) and two females (mean ± SD age 22 ± 1 years, stature 161.5 
± 1.5 cm, body mass 57 ± 3 kg, 1 RM squat 68.5 ± 2.5 kg) consented to take part in this study. 
All participants were experienced resistance-trained athletes, with a minimum of three years 
training history, who had consistently used a full-squat technique in their own hypertrophy 
programmes. To be included in this study, the participants had to be injury-free and train at 
least three times per week using resistance exercises that fall within the typical hypertrophy 
training sets and repetition ranges described in the literature (ACSM, 2009), with at least three 
years of training history. The BCAA group had 3.9 ± 0.7 years of resistance training 
experience, while the placebo group had 4.3 ± 1.6 years. Participants were initially screened 
for any recent injuries or movement compensations that may cause pain or discomfort when 
squatting or factors influencing their ability to perform the required moments. Ethical approval 
was granted for this study by the Institutional ethics committee (SMEC_2016-17_001).  
 
Design 
Two weeks prior to testing, participants were told to cease any use of nutritional supplements, 
additional to their normal diet, such as protein supplements, creatine and amino acids. The 
participants were advised to avoid any drugs with anti-inflammatory properties and not to use 
compression garments or seek or therapeutic intervention, such as hydrotherapy treatments or 
forms of massage. They were also provided with a diet plan to follow from 48-h before the 
  
study until their final testing day. The intended energy content of their diet plans was based on 
published approaches (Alfonzo-Gonzales et al., 2004) and provided three options of breakfast, 
lunch, dinner and snacks. For consistency, the meal options comprised a macronutrient 
composition of 50% carbohydrate, 15% protein (of similar amino acid content) and 35% fat. 
Caloric intake was monitored throughout the study using ‘My Fitness Pal’ (MyFitnessPal Inc, 
Austin, TX). The reported caloric intake of the participants during the study (males and 
females) was 2486 ± 412 kcal/day and 2667 ± 449 kcal/day in the BCAA and placebo groups, 
respectively. The actual reported macronutrient compliance during the study was: 46 ± 9 % 
carbohydrates, 15 ± 3 % protein and 39 ± 8 % fat. The participants visited the laboratory at the 
same time of day (1000-1100) on four separate days, approximately 1-2-h after breakfast. 
During visit 1, the participants familiarized with the testing procedures, were tested for their 1 
RM and weighed for subsequent calculation of the BCAA supplement. The participants were 
given specific instructions for how to perform a back squat, including tempo and joint 
positioning, as this would be the mode of muscle-damage during the study. Visit 1 was carried 
out 72-h before the next visit (visit 2) and no other exercise was performed in between. 
Familiarization was deemed to be sufficient after one visit as the participants were consistent 
in their performance on all tests and indicated that they were comfortable in performing them. 
After visit 1, the participants were assigned to one of the two conditions (BCAA supplement 
or placebo) in a double-blind, matched-pairs design. The participants were matched on body 
mass, sex and 1 RM strength. The supplements (placebo or BCAA) were consumed 30-min 
before and after the muscle damage protocol. Over the following 48-h, the supplements were 
provided 30-min before and after re-testing. The supplements were prepared by an independent 
laboratory technician, who was also responsible for the random allocation of participants to 
each group. The randomisation was carried out by assigning each participant a number and 
using publicly available software to allocate their group (http://www.randomization.com/). On 
  
visit 2, the participants had capillary blood samples drawn from the finger for the measurement 
of baseline creatine kinase (CK) and then performed a battery of tests in the following order: 
perceived soreness, lower-limb isometric strength and countermovement jumping. After the 
baseline testing, the participants were supervised through the muscle-damage protocol. One 
hour after the damage protocol, the same measurements were taken. Visits 3 and 4 followed 
24-h and 48-h, respectively, after the muscle damage protocol, where the same battery of tests 
were performed.  
 
Procedure 
Knee-extensor isometric strength  
To test the maximal isometric strength of the knee-extensor muscles, each participant sat on a 
custom made, adaptable strength chair, with their back and knees fully supported. Their knee 
was firmly fixed at 100˚ and their hips at 110˚, which was verified using a goniometer. Their 
right leg was firmly strapped to the chair across the mid-thigh, whilst their ankle (immediately 
above malleoli) was fixed to a strain gauge (Interface SSM-AJ-500 Force Transducer; 
Interface, Scottsdale, AZ; 0.05% maximum error), sampling at 1000 Hz. The strain gauge 
recorded force as alteration in voltage. Calibration of the strain gauge with a known mass 
demonstrated the relationship between voltage and Newtons as linear, allowing determination 
of a regression formula to convert voltage to Newtons. A second calibration was performed 
with the same weights at the completion of testing, producing an ICC of 0.99. The strain gauge 
was attached to the participant using a high tension belt. The chair set-up was replicated for 
each participant in subsequent trials. Their upper-body was also tightly fitted to the chair with 
two straps across each shoulder, which they were instructed to grip with their hands throughout 
the testing. A command of ‘3-2-1-GO’ was given, after which the participants performed a 
maximal isometric knee extension for 5-s. Non-specific verbal encouragement was provided 
  
to the participants for motivation. Participants performed three maximal tests, separated by 2-
min. A maximal voluntary contraction (MVC) was determined as the highest of three values. 
If the peak force (N) produced by participants systematically increased across the three tests, a 
fourth test was conducted. The reliability of this procedure was 2% (coefficient of variation; 
CV). 
 
Counter-movement jumping (CMJ) 
Participants performed a CMJ on a jump mat (Probiotics Inc, Huntsville, AL, USA) by standing 
with their feet at shoulder width, hands on hips and descending to ~90˚ before propelling 
themselves vertically to the highest possible height, keeping their legs fully extended. 
Standardised non-specific motivation and cues were provided to facilitate performance. The 
participants performed three jumps, separated by 2-min and the highest jump height (cm) was 
recorded. If the values systematically increased across the three tests, a fourth test was 
conducted. The test re-test reliability of this procedure was 1.2% (CV).  
 
Blood sampling and analysis 
The index fingertip of the subject was cleaned using a sterile alcohol swab and allowed to dry. 
Capillary blood was drawn from the finger and a sample of whole blood (30 μL) was collected 
into a heparinised capillary tube. The whole blood was centrifuged at 3000 rpm (4°C) for 5 
min, and the resultant plasma was removed and stored at -80°C until subsequent analysis. 
Plasma CK was measured using a chemistry analyser (Rx Monza, Randox Laboratories Ltd., 
Crumlin, Antrim, UK). The intra-sample CV of the analyser is < 4% CV at high and low 
concentrations and the expected baseline sample range is 37-2755 IU/L for CK, according to 
manufacturer’s guidelines. To eliminate inter-assay variance, all samples were analysed in the 
same assay run 
  
 
Perceived soreness 
The participants were asked to rate their perceived muscle soreness in the lower-limbs from 0-
10 on a 200 mm Visual Analogue Scale (VAS). The numbers were concealed from the 
participant on the reverse of the scale, whilst the verbal anchors of no muscle soreness (~0 on 
reverse), soreness upon movement (~5 reverse) and too sore to move (~10 reverse) were 
observed from the front of the scale. To do this, the participants performed a 5-s isometric 
squat, with their ankles, knees and hips at 90˚ and, after 5-s, moved a sliding scale to the number 
which they perceived to correspond to their level of soreness (Howatson et al., 2012).  
 
Supplementation 
Each participant was supplemented with either a placebo or a BCAA beverage, both of which 
contained 0.25 g/kg body mass of dextrose dissolved into 300 ml of water, thus ensuring drinks 
were indistinguishable in taste. The BCAA drinks were supplemented at a dosage of 0.087 g/kg 
body mass (Børsheim et al., 2002), consisting of leucine, isoleucine, and valine in a 2:1:1 ratio 
(Myprotein, Cheshire, UK). This dosage of AA has been shown to promote recovery from 
resistance exercise (Børsheim et al., 2002) and the ratio of leucine, isoleucine and valine was 
pre-determined by the manufacturer. Drinks were consumed 30-min before and immediately 
after the muscle damage protocol (Jackman et al., 2010). Over the following 48-h, the 
supplements were provided 30-min before and immediately after re-testing. On the final day, 
the supplement was taken with breakfast and 30-min before testing to provide two doses.   
 
Muscle-damage protocol 
A standardised warm-up was performed on the day, comprising walking, dynamic stretching 
and squatting up to 30% of the final load. The participants then performed back squats at an 
  
intensity of 70% of 1 RM for 10 repetitions across 6 sets (ACSM, 2009). Two minutes rest was 
given between sets, where participants remained standing and were free to walk around a 10 m 
x 10 m area. To replicate an optimal hypertrophy session, the participants were told to perform 
all repetitions as per their familiarisation, with an eccentric phase of 3-s, followed by a 
moderate 2-3 s concentric phase (Schoenfeld, 2010). If a set dropped below 8 repetitions, or 
the investigator judged the quality of technique to regress, then the weight was decreased by 
10% until the desired repetition range or lifting form was achieved. 
 
Statistical analyses 
Based on best-practice recommendations for research in sports nutrition (See Burke, 2008), 
effect sizes (ES) and magnitude-based inferences (MBIs) were used to identify mechanistic 
differences in the dependent variables between the two experimental conditions (placebo or 
BCAA). All of the dependent variables were expressed as change relative to baseline. Effect 
sizes were defined as; trivial = 0.2; small = 0.21–0.6; moderate = 0.61–1.2; large = 1.21–1.99; 
very large > 2.0 (Batterham and Hopkins, 2006). Raw data were log-transformed to account 
for non-uniformity of effects. Threshold probabilities for substantial effects based on the 90% 
confidence limits were: <0.5% most unlikely, 0.5–5% very unlikely, 5–25% unlikely, 25–75% 
possibly, 75–95% likely, 95–99.5% very likely, 99.5% most likely. Thresholds for the 
magnitude of the observed change in the dependent variables were determined as the within-
participant standard deviation × 0.2 (small) 0.6 (moderate) and 1.2 (large). Effects with 
confidence limits across a likely small positive or negative change were classified as unclear 
(Hopkins et al., 2009). The uncertainty of effects was based on 90% confidence limits for all 
variables. A custom spreadsheet was used to perform all of the calculations 
(http://www.sportsci.org/.). 
 
  
Results 
There were trivial differences between BCAA and placebo groups for the total energy intake 
(2486 ± 412 kcal/day cf. 2667 ± 449 kcal/day; trivial, unlikely), carbohydrate (1157 ± 354 
kcal/day cf. 1230 ± 300 kcal/day; trivial, unlikely), fat (980 ± 283 kcal/day cf. 1049 ± 275 
kcal/day; trivial, unlikely) and protein energy intake (378 ± 79 kcal/day cf. 394 ± 101 kcal/day; 
trivial, unlikely). 
 
Changes in isometric strength (% baseline) are presented in Figure 1 (mean ± SD). There were 
large reductions in isometric strength between baseline and post-exercise for the BCAA group 
(1031 ± 273 N cf. 976 ± 238 N, respectively most likely ↓), whilst the placebo group showed 
very large changes (899 ± 248 N cf. 734 ± 186 N, respectively; most likely ↓). By 24-h post-
testing, the reduction in strength remained very large for the placebo group (most likely ↓) and 
large for the BCAA group (most likely ↓), which were subsequently reduced to moderate, 
unclear changes among the placebo and BCAA conditions at 48-h. Both groups did not return 
to baseline strength levels during the study. Pairwise between-group tests revealed a greater 
reduction in isometric strength at 24-h in the placebo group compared to the BCAA group 
(moderate, likely ↓), indicating a delayed recovery of muscle function. 
 
*******Figure 1 near here******* 
 
Changes in CK concentration (% baseline) are presented in Figure 2 (mean ± SD). There were 
moderate increases in CK between baseline and post-exercise for the BCAA group (339 ± 77 
IU/L cf. 783 ± 407 IU/L, respectively; very likely ↑), whilst there were small, unclear increases 
in the placebo group (357 ± 121 IU/L cf. 538 ± 235 IU/L, respectively ). By 24-h post-testing, 
the increase in CK was large and most likely for both groups, which remained large, and most 
  
likely between baseline and 48-h. Both groups did not return to baseline CK levels during the 
study. Pairwise between-group tests revealed large, possible increases in CK concentration at 
24-h and 48-h in the BCAA group compared to the placebo group. 
 
*******Figure 2 near here******* 
 
Changes in CMJ height (% baseline) are presented in Figure 3 (mean ± SD). There were 
moderate, very likely reductions in CMJ height between baseline and post-exercise for the both 
groups (BCAA = 56.3 ± 6.9 cm cf. 54.6 ± 8.2 cm; Placebo = 55.4 ± 5.4 cm cf. 52.8 ± 6.2 cm). 
By 24-h post-testing, the reduction in CMJ height was very large and most likely for both 
groups, which improved to a trivial, and unclear for both groups between baseline and 48-h, 
indicating a return to baseline. Pairwise between-group tests revealed small, likely reductions 
in CMJ height at post-exercise and 24-h in the placebo group compared to the BCAA group. 
 
*******Figure 3 near here******* 
 
Changes in perceived muscle soreness (% baseline) are presented in Figure 4 (mean ± SD). 
There were large, most likely increases in perceived muscle soreness between baseline and 
post-exercise for the both groups (BCAA = 1.6 ± 0.9 AI cf. 8.6 ± 3.4 AI; Placebo = 1.8 ± 8.6 
AI cf. 8.6 ± 4.4 AI). By 24-h post-testing, the increase in perceived muscle soreness remained 
large and most likely for both groups, which improved to a trivial, and unclear between 
baseline and 48-h, indicating a return to baseline. Pairwise between-group tests revealed small, 
likely increases in perceived muscle soreness at 24-h and 48-h in the placebo group compared 
to the BCAA group. 
 
  
 
*******Figure 4 near here******** 
 
 
Discussion  
We investigated the effects of BCAA supplementation on recovery from muscle damage after 
a hypertrophy-based protocol, among participants regularly taking part in this form of exercise. 
All of the participants in this study exhibited indirect signs of exercise-induced muscle damage, 
with both the placebo and BCAA groups declining in strength and CMJ height and increasing 
DOMS and CK concentration across the 48-h recovery period. However, as hypothesised, the 
primary finding of this study was that a BCAA supplement of 0.087 g/kg body mass was 
sufficient to reduce the effects of a hypertrophy-based training session on isometric strength, 
CMJ height and DOMS compared to placebo. The differences between groups were 
predominantly noted at the 24-48-h period, whereby the BCAA group showed differences 
(small to large) in strength, CMJ and DOMS compared to placebo (Figures 1-4), indicating 
faster recovery towards baseline values. That baseline values of strength or CMJ height were 
not re-established after 48-h was not unexpected as other studies have shown that muscle 
function and other performance measures do not return to baseline 72-h to 96-h after muscle 
damage when BCAAs are orally administered (Jackman et al., 2010; Howatson et al., 2012; 
Kirby et al., 2012). Most importantly, our findings support the suggestion that BCAA 
supplementation can increase the rate of recovery in muscle function among well-trained 
habitual weight-lifters, following a muscle damage protocol that mimicked a typical 
hypertrophy training session.  
 
  
Similar findings have been reported previously, where a comparable dosage of a BCAA 
supplement, administered across a 7-day loading period, accelerated the recovery of muscle 
function and DOMS (Howatson et al., 2012). Kirby et al. (2012) also reported an improvements 
in recovery of isometric strength, but not squat jump height, after muscle damage using a short-
term (beginning 30-min prior to exercise) leucine supplementation regime, similar to the 
current study. On this basis, Kirby and co-authors questioned the usefulness of leucine as a 
recovery agent if its effects do not transfer to ballistic tasks. Indeed, others have reported 
similar findings, with no change in vertical jump height between placebo and BCAA groups 
after muscle damage (Howatson et al., 2012). In disagreement with these studies, we found that 
CMJ height was recovered faster in the BCAA group compared to placebo at 24-h post-
damage. The use of a standard CMJ test, opposed to a static jump (Kirby et al., 2012), might 
partly explain this difference as it is known that movements involving the stretch-shortening 
cycle (SSC) can be effected by muscle damage, partly owing to structural changes in non-
contractile elements and an associated loss of muscle-tendon stiffness (Komi, 2000). In vitro 
studies have shown that leucine administration can promote the restoration of damaged 
connective tissue in rat skeletal muscle (Perieira et al., 2014), which is responsible for the 
transfer of energy between the muscle and tendon structures (Turrina et al., 2013). Therefore, 
it is feasible that the repair of damaged connective tissue was facilitated by BCAA 
supplementation, thus supporting energy transfer during SSC movements. There are other 
mechanisms, such as impairment of reflex-sensitivity (Komi, 2000) that might explain the 
poorer CMJ performance post-muscle damage. The lowered DOMS after BCAA 
supplementation is likely to have caused less neural inhibition, thus enabling improved reflex 
sensitivity and performance (Nicol et al., 2003). Based on the above findings, we suggest that 
long-term BCAA supplementation may not be necessary for the recovery of isometric muscle 
function after muscle damage and that this occurs in parallel to the recovery of CMJ 
  
performance. Of course, these differences could also be attributed to the application of an 
ostensibly more appropriate statistical technique (Batterham and Hopkins, 2006; Burke, 2008) 
compared to previous studies, particularly when the difference between groups is small.   
 
Heavy resistance exercise has been shown to induce the release of muscle proteins, such as 
CK, into the blood stream (Kraemer et al., 1993). As anticipated, CK concentration increased 
in the 24-h after muscle damage in both conditions, reflecting disruption of the sarcolemmal 
membrane. However, BCAA supplementation appeared to increase CK compared to placebo 
in the current study, which was not expected. Our findings add to the equivocality of current 
research, with some reporting no change in the CK response after muscle damage (Jackman et 
al., 2010) and others showing an attenuation of the CK response after mixed amino acid or 
BCAA supplementation (Nosaka et al., 2006; Howatson et al., 2012; Kirby et al., 2012). The 
current findings could be attributed to the well-described intra-individual CK response to 
muscle damage, resulting in large standard deviations and random variations in CK values 
across the subsequent days (Clarkson and Ebbeling, 1988). Irrespective of the reasons for these 
findings, the current data question the supposition that CK efflux after muscle damage is 
blunted by BCAA availability. Furthermore, given that soreness was also lower in the BCAA 
group, despite higher CK values, these findings do not support the involvement of BCAAs in 
a proposed mechanism that relies on parallel changes in these measures to explain a reduction 
in secondary muscle damage (Howatson et al., 2012). These findings support the suggestion 
that CK might not be a useful single marker of muscle damage (Chrismas et al., 2013).    
 
This was the first study to test the effect of BCAA supplementation on muscle damage in a 
sample of experienced resistance-trained athletes, who perform habitual hypertrophy training, 
using a mode of exercise that reflects their day-to-day activities. Our findings show that muscle 
  
damage is caused among athletes of this type and that acute BCAA supplementation, prior to 
and during the recovery period, is capable of accelerating recovery in the 24-48-h after a muscle 
damaging bout of exercise. This is particularly relevant to athletes taking part in regular 
hypertrophy training as programmes of this type necessitate a maximum of 48-h between 
training days. In addition, this is the first study to prescribe and monitor the daily diet of 
resistance-trained participants, thus controlling the total energy and macronutrient intake 
during the BCAA supplementation period. This is an extremely important aspect of the current 
study because, without such measures being taken, the available energy, as well as the amount 
and quality of amino acids being ingested alongside the supplement is unknown. Indeed, lack 
of suitable dietary control has been suggested as a major limitation among studies that have 
investigated the effects of BCAA or protein supplementation on recovery from muscle damage 
(Pasiakos et al., 2015). Our findings, therefore, support studies that have reported positive 
effects of acute BCAA (or isolated leucine or amino acid) supplementation on recovery from 
muscle damage (Kirby et al., 2012) and extend this to diet-controlled, experienced resistance-
trained athletes.  
 
Whilst the diet of the current participants was under control, it should be stated that, given the 
design of this study which did not include a separate mixed amino acid group, it is unclear 
whether the accelerated recovery was due to the BCAA alone mixture or the addition of amino 
acids to the diet. Future studies should extend the current work by including amino acid and 
isolated leucine groups to the experimental design. The isolated leucine group is a particularly 
important part of this suggestion as leucine has the most potent effects on muscle protein 
synthesis via mTor pathways (Philips, 2009), which is not the case for the remaining BCAAs, 
isoleucine and valine (Churchward-Venne et al., 2014). BCAAs, collectively, have long-held 
presumed stimulatory effects on protein synthesis (Blomstrand et al., 2006), which might 
  
explain their inclusion in recovery drinks. Indeed, this was part of the rationale for the current 
study. However, given the reported competition between leucine, isoleucine and valine for 
cellular transport and subsequent metabolism (Cynober, 2002), it is possible that valine and 
isoleucine inhibited the effects of leucine on muscle protein synthesis and that the combination 
of all three BCAAs is unnecessary or detrimental to muscle recovery (De Bandt and Cynober, 
2006). 
 
Administration of leucine-rich amino acids has also been shown to reduce the appearance of 
inflammatory cytokines, whilst increasing muscle protein synthesis after eccentric exercise in 
rodents (Kato et al., 2016) and after endurance exercise in athletes (Rowlands et al., 2016). 
Muscle soreness is partly related to local inflammation, which is a necessary part of the 
recovery process that follows acute mechanical damage of the myofibres (Howatson and van 
Someren, 2008). The proposed anti-inflammatory effects of leucine post-exercise might 
explain its capacity to lower muscle soreness. However, there are putative roles for all BCAA 
during the acute inflammatory phase of muscle damage. This is because of the known 
transamination of all BCAA into glutamate and, thus, contribution to the glutamate-glutamine 
pool, which is a known substrate for inflammatory cells (Nicastro et al., 2012). It is, therefore, 
important that future research is designed to examine the effects of isolated BCAA, most 
notably leucine, on the inflammatory responses to resistance exercise and associated muscle 
soreness.  
 
Given the unanticipated CK response after the muscle-damaging exercise in the current study, 
it would have been useful to measure other blood markers of muscle damage, such as 
myoglobin, which is known to increase after strenuous exercise (Brancaccio et al., 2010) and 
can be reduced after protein supplementation (Cockburn et al., 2008). This would have helped 
  
to comprehend the unexpected CK response and provided a more comprehensive 
understanding of the mechanisms by which a BCAA supplement is able to accelerate recovery 
muscle damage, without appearing to alter the level of blood proteins. Indeed, replication of 
this study using different combinations of BCAA dosage would be beneficial, given the reports 
that question the necessity of valine and isoleucine as part of a BCAA supplement (De Bandt 
and Cynober, 2006; Churchward-Venne et al., 2014). Furthermore, future studies should 
investigate the chronic effects of BCAA supplementation on recovery from muscle damage as 
athletes undertaking hypertrophy training will require long term recovery strategies and the 
findings of this study were limited to a 48-h recovery period. However, the diet control and 
supervised supplementation regime that were imposed herein to isolate the acute effects of 
BCAA supplementation would be methodologically challenging for future researchers, yet not 
impossible to achieve. 
 
Conclusion 
Acute oral supplementation of BCAAs at a concentration of 0.087 g/kg body mass was 
sufficient to increase the rate of recovery in isometric strength, CMJ height and perceived 
soreness compared to placebo after a hypertrophy-based training session among resistance-
trained athletes. This means that, based on a 100 kg athlete supplementing twice daily, as little 
as 17.2 g/day of BCAAs is necessary to accelerate recovery from hypertrophy training sessions. 
However, further studies are required to understand whether the provision of BCAAs, the 
amino acid content alone or isolated BCAAs are mediating this response. This study also 
highlights the importance of controlling the energy and macronutrient intake of participants 
during research of this type, owing to the potential confounding influence of unaccounted 
dietary food sources on recovery from muscle damage.      
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Figure 1. Changes in isometric strength (% baseline) after muscle damage among the placebo 
and BCAA groups. † = moderate difference between conditions at that time point. 
 
Figure 2. Changes creatine kinase concentration (% baseline) after muscle damage among the 
placebo and BCAA groups. * = large difference between conditions at that time point. 
 
Figure 3. Changes counter-movement jump (CMJ) height (% baseline) after muscle damage 
among the placebo and BCAA groups. ¥ = small difference between conditions at that time 
point. 
 
Figure 4. Changes perceived soreness (% baseline) after muscle damage among the placebo 
and BCAA groups. ¥ = small difference between conditions at that time point. 
 
